Author

Kristine J. Fernandez

Garvan Institute of Medical ResearchORCID 0009-0002-5509-6807Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Catherine Elizabeth CaldoniD· 2 shared Zoe PhaniD· 2 shared Antonia L. CadelliD· 1 shared Carla L. AlvesiD· 1 shared Celine E Wiharja· 1 shared Christine S Lee· 1 shared Daniel A. ReediD· 1 shared David R. CroucheriD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Catherine Elizabeth CaldonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyJournal of Cellular and Molecular MedicinePeer-reviewedSep 1, 2025

Unmatched cell line collections are not optimal for identification of PARP inhibitor response and drug synergies

Zoe Phan, Kristine J. Fernandez, Catherine Elizabeth Caldon

This study shows that unmatched cell line collections are not reliable for identifying PARP inhibitor response and synergies, and suggests isogenic models are more accurate.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJan 8, 2025

JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer

Sarah Alexandrou, Christine S Lee, Kristine J. Fernandez…·Catherine Elizabeth Caldon

This study identifies JNK pathway suppression as a driver of resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer, with implications for patient stratification.

DOI 10.1101/2025.01.08.631992

humangenetic perturbation / CRISPR

𝕏 PostBluesky